|
ARHGEF9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.73579969578952E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.02170005367964E-09 |
| Normal-vs-Stage2 |
1.633770E-02 |
| Normal-vs-Stage3 |
6.23530116428128E-11 |
| Normal-vs-Stage4 |
2.26159999616726E-08 |
| Stage1-vs-Stage2 |
1.237710E-02 |
| Stage1-vs-Stage3 |
4.408100E-02 |
| Stage1-vs-Stage4 |
1.048760E-01 |
| Stage2-vs-Stage3 |
3.041400E-04 |
| Stage2-vs-Stage4 |
2.036600E-03 |
| Stage3-vs-Stage4 |
9.134600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.36269884265516E-11 |
| Normal-vs-AfricanAmerican |
1.909610E-01 |
| Normal-vs-Asian |
4.35710000301626E-08 |
| Caucasian-vs-AfricanAmerican |
1.018610E-01 |
| Caucasian-vs-Asian |
7.042200E-01 |
| AfricanAmerican-vs-Asian |
1.459770E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.11679999998038E-06 |
| Normal-vs-Female |
1.19330101355786E-11 |
| Male-vs-Female |
1.253570E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.76830003365092E-09 |
| Normal-vs-Age(41-60Yrs) |
1.6195999985591E-08 |
| Normal-vs-Age(61-80Yrs) |
2.33910000002613E-06 |
| Normal-vs-Age(81-100Yrs) |
6.764200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.612000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.466400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.012200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.987800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.853200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.928000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.68810001719567E-09 |
| Classical-VS-Follicular |
1.9001000000074E-06 |
| Classical-VS-Other |
3.898800E-01 |
| Classical-VS-Normal |
2.43109976594269E-10 |
| Tall-VS-Follicular |
1.4210854715202E-14 |
| Tall-VS-Other |
1.225590E-01 |
| Tall-VS-Normal |
1.62436730732907E-12 |
| Follicular-VS-Other |
2.663600E-02 |
| Follicular-VS-Normal |
3.713700E-02 |
| Other-VS-Normal |
5.201700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.2867000000204E-06 |
| Normal-vs-N1 |
1.27230448399018E-11 |
| N0-vs-N1 |
4.625600E-04 |
|
|
